ANURAS2024-10-012024-12-31 ANURAS2024-10-012024-12-31 ANURAS2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member ANURAS2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member ANURAS2024-12-31 ANURAS2024-10-012024-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ANURAS2024-10-012024-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member ANURAS2024-10-012024-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ANURAS2024-10-012024-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss02Member ANURAS2024-10-012024-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member ANURAS2024-10-012024-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss02Member ANURAS2024-10-012024-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member ANURAS2024-10-012024-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 543275 ANURAS NOTLISTED Anupam Rasayan India Limited Equity 2024-04-01 2025-03-31 2025-02-13 2025-02-06 INR Millions Third quarter 17:36:00 18:24:00 2025-02-13 2025-02-13 Not applicable Single segment Manufacturing of Industrial Chemicals 2024-10-01 2024-12-31 Unaudited Consolidated 3901404000.00 -35469000.00 3865935000.00 2726816000.00 0.00 -1160711000.00 200934000.00 319637000.00 292950000.00 891315000.00 3270941000.00 594994000.00 0.00 594994000.00 143187000.00 -90292000.00 52895000.00 0.00 542099000.00 0.00 0.00 0.00 0.00 542099000.00 -24832000.00 517267000.00 281920000.00 260180000.00 257080000.00 260180000.00 1099313000.00 10 2.57 2.57 0.00 0.00 2.57 2.57 [1] The above Consolidated financial results for the quarter and nine months ended December 31, 2024, have been prepared by the Company in accordance with Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended) and were reviewed by the Audit Committee of the Board and thereafter were approved and taken on record by the Board of Directors in their meeting held on February 13, 2025. [2] Based on the management approach as defined in Ind AS 108 - Operating Segments, the Chief Operating Decision Maker (CODM) evaluates the company's performance and allocates resources based on the analysis of various performance indicators of business segment/s in which the company operates. The Company is primarily engaged in the business of custom synthesis and manufacturing of specialty chemicals which the management and CODM recognise as the sole business segment. Hence, disclosure of segment-wise information is not required and accordingly not provided. [3] The Company has made investment in the following subsidiary companies and an associate company of wholly owned subsidiary of the Company as on December 31, 2024 and accordingly, consolidated financial results are prepared for the quarter and nine months ended on December 31, 2024. Name of the Subsidiary Nature of relationship (a) Jainam Intermediates Private Limited Wholly-owned subsidiary (b) ARIL Transmodal Logistic Private Limited Wholly-owned subsidiary (c) ARIL Fluorospeciality Private Limited Wholly-owned subsidiary (d) Anupam Japan GK Wholly-owned subsidiary (e) Anupam Europe AG Wholly-owned subsidiary (f) Anupam USA, LLC Wholly-owned subsidiary (g) Anupam General Trading FZE Wholly-owned subsidiary (h) Tanfac Industries Limited Subsidiary Company over which the Company exercises effective control (i) Tangent Science Private Limited An associate Company of wholly owned subsidiary of the Company [4] The figures of the previous period have been re-grouped / rearranged and / or recasted wherever considered necessary. Single segment 2024-04-01 2024-12-31 Unaudited Consolidated 9383005000.00 44541000.00 9427546000.00 6539532000.00 0.00 -2869724000.00 552010000.00 809993000.00 716191000.00 2582196000.00 8330198000.00 1097348000.00 0.00 1097348000.00 265754000.00 -138839000.00 126915000.00 0.00 970433000.00 0.00 0.00 0.00 0.00 970433000.00 -23135000.00 947298000.00 487810000.00 482620000.00 461480000.00 485820000.00 1099313000.00 10 4.44 4.44 0.00 0.00 4.44 4.44 Other Expenses 891315000.00 Other Expenses 2582196000.00 Gain/(loss) on remeasurements of the defined benefits plan -2664000.00 Income tax (expense)/income on remeasurements of the defined benefits plan 930000.00 Gain/(loss) on remeasurements of the defined benefits plan 334000.00 Income tax (expense)/income on remeasurements of the defined benefits plan 466000.00 -1734000.00 800000.00 0.00 0.00 Effective portion of gain/(loss) on hedging instruments in a cash flow hedge -35941000.00 Income tax (expense)/income on effective portion of gain/(loss) on hedging instruments in a cash flow hedge 12843000.00 Effective portion of gain/(loss) on hedging instruments in a cash flow hedge -36267000.00 Income tax (expense)/income on effective portion of gain/(loss) on hedging instruments in a cash flow hedge 12332000.00 -23098000.00 -23935000.00 0.00 0.00